Recent fundraising milestones and clinical advances highlight the growing prominence of epigenetic and gene editing therapies in biotech. China-based Epigenic Therapeutics secured $60 million in Series B funding to advance CRISPR-based epigenetic therapies targeting chronic hepatitis B, aiming for transformative cures. Concurrently, notable studies dissect DNA methylation dynamics and X-chromosome inactivation in human placenta cells, enriching understanding of epigenetic regulation with potential clinical implications. These developments mark continued momentum for epigenetic modulation as a therapeutic frontier.